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Summary 
We have cloned a novel mouse CC chemokine cDNA from the lung during an allergic inflam- 
matory reaction. The protein encoded by this cDNA is chemotactic for eosinophils, mono- 
cytes, and lymphocytes in vitro and in vivo. Based on its similarities in sequence and function 
with other CC chemokines, we have named it mouse monocyte chemotactic protein-5 
(mMCP-5). Under noninflammatory conditions, expression of mMCP-5 in the lymph nodes 
and thymus is constitutive and is generally restricted to stromal cells. Neutralization ofmMCP-5 
protein with specific antibodies during an allergic inflammatory reaction in vivo resulted in a 
reduction in the number of eosinophils that accumulated in the lung. Moreover, mMCP-5 
mtkNA expression i  vivo is regulated ifferently from that of other major CC chemokines in
the lung during the allergic reaction, including Eotaxin. The presence oflymphocytes is essen- 
tial for expression of mMCP-5 by alveolar macrophages and smooth muscle cells in the lung, 
and the induction of mMCP-5 RNA occurs earlier than that of the eosinophil chemokine 
Eotaxin during allergic inflammation. In contrast to Eotaxin, mR.NA for mMCP-5 can be pro- 
duced by mast cells. From these results, we postulate that mMCP-5 plays a pivotal role during 
the early stages of allergic lung inflammation. 
T he late phase of an asthmatic reaction is mediated by a swarm of leukocytes that are recruited to the lung by 
cytokines and chemotactic factors (1). The mechanism(s) 
by which the different populations of leukocytes are re- 
cruited and how they regulate the attraction and function 
of other leukocytes present at the inflammatory site is 
poorly understood. However, there is evidence to suggest 
that the accumulation of eosinophils at sites of allergic reac- 
tions may be directly associated with the presence of lym- 
phocytes and with the production by T cells of cytokines, 
which are known to stimulate osinophil maturation, acti- 
vation, and survival, or to modulate the expression of adhe- 
sion molecules (2, 3). 
At the present time, the accepted paradigm for leukocyte 
extravasation is that the selective homing of particular cir- 
culating leukocytes into inflamed tissues takes place via the 
generation of chemotactic gradients created by chemoat- 
tractants or by specific cytokines termed chemokines (4, 5). 
Most chemokines can be grouped as members of either the 
CXC (or) or CC (13) family to denote the spacing of the 
first two cysteine residues of the mature proteins. The CXC 
chemokine family seems to act preferentially on neutro- 
phils and includes, among others, platelet factor 4, NAP- l /  
IL-8, gro, IP-10, and ENA-78. The CC family has been 
described as attracting several eukocyte subsets, but not 
neutrophils, and includes macrophage inflammatory protein 
(MIP)I-loL, -[3, monocyte chemotactic protein-1 (MCP-1)/JE, 
MCP-2, MCP-3, Eotaxin, and RANTES (6). The rele- 
vance of chemokines in the migration of leukocytes to in- 
flammatory sites in vivo has been demonstrated in various 
experimental systems of differing complexity (7-9). 
Because of their broad chemotactic specificities, CC 
chemokines could play a central role in the development 
and maintenance of the leukocytic infiltration found in the 
lung during allergic inflammation (eosinophils, lympho- 
cytes, monocytes, etc., and lack of a significant and/or pre- 
dominant infiltration of neutrophils). We and others have 
1Abbreviations u ed in this paper: BMCMC, bone marrow-cultured mast 
cells; h, human; m, mouse; MCP, monocyte chemotactic protein; MIP, 
macrophage inflammatory protein; tkT, reverse transcnptase. 
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identified and studied several CC chemokines, including 
mouse Eotaxin, in the lungs of  mice that were rendered 
eosinophilic by repeated exposure to aerosolized OVA 
(10--13). 
The work reported here represents our continued efforts 
in the identification and study of  CC chemokines that 
could be integral in promoting the complex leukocyte in- 
filtration that is present in the lung during allergic reactions. 
We have isolated a novel cDNA from mouse hypereosino- 
philic lungs by PC1L amplification based on consensus e- 
quences that are present in CC chemokine genes. This 
novel mouse CC chemokine has strong homology with 
human (h)MCP-1. The chemotactic activity of  the protein 
encoded by this gene in vitro, as well as after in vivo ad- 
ministration, and the regulation of  the expression and func- 
tion of  this gene during lung eosinophilia re presented here. 
Materials and Methods 
Mice and In Vivo Procedures. 8-10-wk-old male and female 
C57BL/6J and RAG-l-deficient mice were purchased from the 
Jackson Laboratory (Bar Harbor, ME), and kept in the Center for 
Blood Research Specific Pathogen Free mouse facihty (Harvard 
Medical School). CD3e-transgenic mice (14) were kindly pro- 
vided by Dr. C. Terhorst (Beth Israel Hospital, Boston, MA). 
OVA-induced pulmonary eosinophilia (Sigma Immunochemi- 
cals, St. Louis, MO) was generated in these mice (three individual 
experiments, n = 10) as previously described (10). 
Peritoneal recruitment assays in vivo with mouse (m)MCP-5 
protein were performed after injection of 400 or 800 Ixl i.p. of 
mMCP-5 recombinant protein-containing conditioned media 
(see below) or control conditioned media. At different time 
points after injection (0, 1, 2, 3, or 4 h), (three individual experi- 
ments, n = 8-13 for test and control mice per time point and 
dose), leukocytes recovered from peritoneal lavage were analyzed 
and enumerated. For the coinjection experiments, bacterial rm- 
Eotaxin (0.5 &g/200 Ixl per mouse; Peprotech, Inc., Rocky Hill, 
NJ) was administered lntraperitoneally simultaneously with either 
400 or 800 Ixl ofmMCP-5 containing conditioned media. In one 
series of experiments, lower doses of Eotaxxn (0.2 Ixg/mouse) 
were coinjected with lower doses of mMCP-5 (100 Ixl/mouse). 
Control mice were injected intrapentoneally with (a) rmEotaxin 
protein and control conditioned media; (b) PBS and mMCP-5-con- 
taining conditioned media; and (c) PBS and control conditioned 
media. All doses and volumes were exactly the same as those 
given to test mice. At different ime points after coinjection of 
mMCP-5-containing conditioned media and rmEotaxm (1, 2, 3, 
or 4 h; three individual experiments, n = 4-12, for test and con- 
trol mice per time point and dose), recovered cells from the peri- 
toneum were analyzed. In one series of blocking experiments, 
mxce were injected with affinity-pufffied neutralizing polyclonal 
antibodies against mMCP-5 (20 p,g/mouse, i.v.) 30 rain before 
OVA administration days 20 and 21, and then analyzed 3 h af- 
ter allergen challenge on day 21. OVA-treated control mice were 
rejected with the same amount of control Ab (purified rabbxt Ig 
fraction; Dako Corp., Carpinteria, CA) at the time points indi- 
cated during treatment. 
Cloning of cDNA by Reverse Transcription (RT)-PCR. A partial 
cDNA fragment of the mMCP-5 gene was cloned from RNA 
extracted from eosinophflic lungs of OVA-sensitized mice (10). 
To clone the full-length mouse mMCP-5 cDNA, we followed 
the same two-step PCR amplification strategy that we used re- 
cendy to clone mouse Eotaxin (10). Specific primers used for ev- 
ery step during the cloning were as follows: first step round 1, 5' 
primer 1 (a chimeric primer containing (dT)l v and sequence of 
the T7 promoter: 5'-TAATACGACTCACTATAGGGATTTT- 
TTTTTTTTTTTTT) and 3' primer (5'-CTCCTTATCCAG- 
TATGGTCC); first step round 2, 5' primer 2 (sequence of the 
T 7 promoter: 5'-TAATACGACTCACTATAGGG) and 3' pnmer 
(designed nested to first 3'-pffmer from the sequence of the 
cloned fragment: 5'-ACAGCTTCCCGGGGACACTG); sec- 
ond step round 1, primers 1 and gene specific 5' primer (designed 
from the 5' sequence of the cloned fragment: 5'-AGAGA- 
CACTGGTTCCTGAC); second step round 2, primers 2 and a 
second gene specific primer (a primer containing sequences 
nested to first 5' primer: 5'-TCTCCCTCCACCATGCAGAG). 
Production of Recombinant mMCP-5 Protein in p3X63 Myeloma 
Cells. The entire coding sequence (from 30 to 450 in the nucle- 
otide sequence) of mMCP-5 cDNA was cloned into the expres- 
sion vector pEFpuro in the sense or antisense orientation and 
transfected into p3X63 myeloma cells as before (10). To partially 
purify mMCP-5 from the tissue culture conditioned media (15), 
20 ml of mMCP-5-containing or control conditioned media was 
applied to a 1-ml Hepaffn column (Pharmacla Fine Chemicals, 
Piscataway, NJ), as recommended bysupplier. The eluate was ap- 
plied to a cation exchange column (mono S; Pharmacia) and 
eluted with a linear gradient from 0 to 1 M NaC1 in 50 mM ace- 
tate buffer, pH 5.0. This eluate was diluted 2.5 times and then 
used for the assays hown in Fig. 2 A (indicated as H.C.). Endo- 
toxin levels were estimated less than 0.1 ng/btg (or 75 U) of 
MCP-5, as assessed by the LAL assay (BioWhittaker, Inc., Walk- 
ersville, MD). 
In Vitro Chemotaxis. The in vitro migration of leukocytes to 
recombinant mMCP-5 was evaluated, in duplicate, using a 24-well 
transwell chamber with a 5-1xm pore (Costar, Cambridge, MA), 
as described previously (10). For neutralization experiments, 1 or 
10 p.g/ml of affinity-purified anta-nuMCP-5 polyclonal annbod- 
xes were preincubated with mMCP-5-containing or control con- 
ditioned media for 15 min at 37°C and then used for eoslnophil 
chemotaxis as described above. Purified rabbit Ig fraction (Dako) 
was used as a control in this assay. After incubation, the transwells 
were removed and the number of cells per well counted in the 
FACScan ® (Becton Dickinson & Co., Mountain View, CA) by 
passing each sample for a constant predetermined time period. A 
constant gate was assigned for each leukocyte subpopulation i
the SSC/FSC window and was used for every sample. When 
necessary, samples were also stained for cell lineage-specific 
markers, and were analyzed as explained below. The chemotactic 
index was calculated as the number of cells that migrated to the 
sample divided by the number of cells that migrated to the nega- 
tive control (control conditioned media). 
Eosinophils were purified from the peritoneum of IL-5-trans- 
genic mice as described previously (10). Monocytes/macrophages 
and neutrophils were obtained from the bone marrow or perito- 
neum after injection of thioglycoUate and percoll gradient separa- 
tion (15). Lymphocytes were obtained from the peripheral blood, 
spleen, LN, or bone marrow after erythrocyte lysis and immuno- 
magnetic depletion of Mac-1 ÷ and Gr-1 + cells, as explained 
above. 
Flow cytometry was performed to determine the cell lineage of 
migratory cells in selected experiments. The migratory cells from the 
assay were incubated with anti-Fc receptor mAb (2.492; Phar- 
Mingen), and were then stained with each one of the following an- 
tibo&es individually: Gr-1 (8C5), Mac-1 (CD1 lb), B220 (CD45R), 
1940 mMCP-5 in Lung Allergic Inflammation 
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IgM, or Thyl.2, conjugated with FITC or PE (PharMingen, San 
Diego, CA). Dead cells were excluded by propidium iodide (Sigma) 
incorporation. Flow cytometry data were acquired with a FACScan ® 
cytometer, and were analyzed with CELLQUEST software. 
Generation and Screening of Polyclonal Sera and mAbs Anti- 
mMCP-5. Polyclonal sera against mMCP-5 was generated ac- 
cording to standard methods using the synthetic peptide CADP- 
KEKWVKNSINHLDKTS, covering amino acids 52-71 in the 
mMCP-5 peptide sequence, coupled to KLH (Pierce Chemical 
Co., Rockford, IL; 17). Rabbit serum was first depleted of anti- 
mouse IgG antibodies by passage over a mouse IgG column, and 
anti-mMCP-5 antibodies were purified from the flowthrough on 
a mMCP-5 peptide (52-71) affinity column. Antibody titers were 
determined by ELISA. 
10-wk-old Wistar rats were immunized in the hind footpad 
with the KLH-coupled mMCP-5 peptide, and cell fusions were 
performed as described before (18). Positive supematants were 
studied in Western blot analysis against mMCP-5 that was pro- 
duced by transfected cells. A total of nine mAbs were obtained 
and characterized byWestern blotting and immunostaining. Four 
mAbs recognized mMCP-5 epitopes that were present in frozen 
sections. One of those, ZY2A11, was used for the experiments 
described here. 
Affinity-purified rabbit polyclonal antibodies and rat mAbs 
were shown to recognize a specific band in a Western blot against 
mMCP-5---containing conditioned media, but not against the 
conditioned media of mock-transfected cells (data not shown). 
This band was specifically competed by preincubation the Ab 
preparations with the mMCP-5 (52-71) peptide used for immu- 
nization (data not shown). 
Southern and Northern Blots. Both were performed following 
standard methods and the following probes: mMCP-5 (0.29-kb 
fragment cloned from 5' RACE), Eotaxin (10), RANTES (19), 
and MIP-let (20). 
Measurement of mMCP-5 and mEotaxin mRNA Expression by 
RT-PCR. For RT-PCR, we followed the methods described 
before (10). The specific primers for mMCP-5 used in PCR are 
as following: 5' primer, 5' -TCTCCCTCCACCATGCAGAG 
and 3' primer, 5' -CTCCTTATCCAGTATGGTCC. 
The macrophage cell lines RAW287 and P388D1 were cul- 
tured with TNF-et (20 ng/ml) for 24 h, and the endothelial cell 
line bEnd3 and the fibroblast cell line NIH3T3 were cultured 
with PMA/Ionomycin (10:500 ng/ml) for 8 h. Macrophages 
were freshly isolated from mouse peritoneal cavity 48 h after in- 
jection ofthioglycollate (1 ml/mouse), and were cultured in vitro 
with TNF-ot (20 ng/rrd) or IFN-~/respectively for24 h. 
The mast cells studied include a cloned, growth factor-inde- 
pendent mast cell hne (C1.MC/C57.1 [21]) or primary cultures of 
bone marrow-cultured mast cells (BMCMC). Primary cultures of 
BMCMC were generated from bone marrow cells isolated from 
BALB/c mice as described previously (21). BMCMC were used 
for experiments at4-6 wk, at which time mast cells represented 
>99% of the cells, as determined by neutral red staining. 
Immunohistochemical Phenotyping and Quantitation of Leukocytes. 
The number and type of leukocytes migrating in response to 
mMCP-5 recombinant protein or to both chemokines (rmMCP-5 
protein and rmEotaxin protein) in peritoneal lavage fluid was de- 
termined as described before (10). To determine the number of 
lymphocytes, monocytes, and macrophages, slides were stained 
with mAb against Thy 1.2 (53-2.1), Mac-1 (M1/70), CD45R/ 
B220 (RA3-6B2) from PharMingen, and Moma-2 from Bio- 
source International (Camanllo, CA) using an avidin/biotin staining 
method as described before and counterstained with hematoxylin. 
The number of leukocyte subtypes was determined in four 
high power fields (magnification of 400; total area = 0.5 mm 2) 
per shde (duphcate slides per mouse and time point were exam- 
ined). Monocytes and macrophages were distinguished from lym- 
phocytes on the basis of expression of Mac-1 and Moma-2 on 
their surface and from each other, based on the difference in size 
and granularity observed after Giemsa counterstaining by light 
microscopy or by flow cytometry. 
Immunohistochemical St ining of Lungs and Lymphoid Tissue for 
mMCP-5. Sections of lungs from OVA-treated mice and of in- 
guinal LN and thymi from unchallenged mice were fixed and 
stained with an mAb directed against mMCP-5 using an avidin/ 
biotin staining method. Sections were overlaid with 20% normal 
rabbit serum in PBS for 15 rain. Lungs were incubated with neat 
anti-mMCP-5 (ZY2All) culture supernatant, and LN and thymi 
were incubated with anti-mMCP-5 ascites at 1/100, both over- 
night at 4°C. Endogenous peroxide was subsequently blocked. 
Bound mAb was visualized by incubation with biotinylated rabbit 
anti-rat Ig diluted in 10% normal mouse serum PBS, and then 
with streptavidin peroxidase complex prepared according to man- 
ufacturer's instructions (all from Dako), and incubated for 1 h. Fi- 
nally, the slides were flooded with peroxidase substrate solution 
before counterstaining with hematoxylin. Control sections were 
included where mAb, biotinylated anti-rat Ig, or streptavidin 
complex were selectively omitted. Control slides of lung were 
also stained with an isotype-matched negative control antibody 
instead of primary antibody. 
Results 
Cloning, Mapping, and Structural Analysis of mMCpo5. 
We have used degenerated ohgonucleotides and PCR to 
clone novel CC chemokine cDNA sequences from RNAs  
extracted from eosinophilia lungs (10). Three distinct 
groups of  150-bp PCR products (including two degenerate 
primers) with different nucleotide sequences were obtained 
(10). According to the sequence from one of  them, one 
specific primer was designed to isolate the 5' partial cDNA 
by 5' RACE cloning strategy. The complete cDNA for 
this gene was then isolated by 3' RACE cloning, which in- 
volved two further rounds of  nested amphfication by PCR 
with primers based on the nucleotide sequence of  the pre- 
viously cloned 5' fragment. 
The cloned full-length cDNA for this novel gene con- 
tains 540 bp, whose nucleotide sequence was confirmed by 
three independent PCR amphfications. It includes an open 
reading frame of  341 bases encoding a protein of  104 
amino acids, a 5' untranslated region of  55 bp, and a 3' un- 
translated region of  145 bp (data not shown. GenBank/  
EMBL/DDBJ  accession number U50712). The mature 
protein is composed of  82 amino acids containing five cys- 
teine residues (Fig. 1 A). No  potential N-glycosylation sites 
are present in this protein. The nucleotide similarity of  this 
gene with other CC chemokines i shown in Fig. 1 B. 
The comparison of  the amino acid sequence of  this novel 
gene with those of  other members of  the CC chemokine 
family (Fig. 1 A) revealed the highest similarity with hu- 
man MCP-1 and MCP-3  (Fig. 1, A and B). Because of  this 
and other features described below, this novel mouse CC 
chemokine gene was named mouse monocyte chemotactic 
1941 Jla et al. 
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Figure 1. Companson of the 
armno acid sequence of the 
mMCP-5 mature pepude with 
that of other CC chemoklnes 
and the phylogeneuc tree of 
members of the CC chemokine 
farmly, including mMCP-5. (A) 
An~no acid sequence alignment 
of mMCP-5 with other human 
and mouse CC chemokines. The 
sequences were ahgned using the 
Clustal method with a PAM250 
residue weight table and default 
settings of gap penalties for pair- 
wise and multiple ahguments of 
3 and 10, respectively (Meg- 
Ahgn; DNASTAR, Inc., Madi- 
son, WI). Armno acid sequences 
of the mature proteins for the 
hMCP-1 (35), hMCP-2 (36), 
hMCP-3 (37), hMCP-4 (38), 
mMCP-1/JE (39; 1-85 armno 
acids), and mEot (10) genes were 
compared to the armno acid se- 
quence of the putauve mature 
mMCP-5 protem. Armno acids 
identical to mMCP-5 are shaded 
in black with numbers across the 
top of the sequence referenced 
to mMCP-5. The cDNA se- 
quence of mMCP-5 has been 
deposited in GenBank/EMBL/ 
DDBJ under the accession um- 
ber U50712. (B) Phylogeneuc 
tree of the CC chemokine farmly 
includmg mMCP-5 (bold and 
underhned). Distances to branch 
points are proportaonal toamino 
acid sequence divergence from 
predicted ancestral sequences. 
Percent sirmlanty between the 
nucleotide sequence of the cod- 
mg regaon or the amino acid se- 
quence of the mature peptide of 
mMCP-5 and those of other CC 
chemokanes are shown at the 
nght of the figure. 
protein-5. Comparison of mMCP-5 mature peptide with 
hMCP-1 mature peptide or with the first 80 amino acids of 
the mMCP-1/JE mature peptide revealed 65 and 45% sim- 
ilarity, respectively (Fig. 1). mMCP-5 is a basic protein (10I 
9.07). The amino acid sequence phylogenetic tree and sim- 
ilarity comparisons with other CC chemokines (Fig. 1 B) 
showed that mMCP-5 is most similar and evolutionarily 
related to hMCP-1. 
The mouse chromosomal location of mMCP-5, which 
was determined by interspecific back-cross analysis (22), re- 
vealed that the single locus encoding for this cDNA is lo- 
cated in the central region of mouse chromosome 11 (data 
not shown). 
To determine the possible existence of a gene homolo- 
gous to mMCP-5 in humans, a southern blot containing 
human genomic DNA was hybridized with an mMCP-5 
cDNA probe. Under conditions of high stringency, a single 
hybridizing band was detected (which had a different size 
from that found when the same blot was hybridized with 
an hMCP-1 probe; data not shown), suggesting the exist- 
ence of an mMCP-5 homologue in humans. 
In Vitro Chemotactic Responses of Leukocytes to mMCPo5. 
To characterize the activities o f  mMCP-5  its expression in 
mammal ian cells was engineered,  as we  have done previ-  
ously (reference 10 and Materials and Methods) .  
Eosinophi l  chemotaxis to mMCP-5  was examined using 
mouse eosinophils (90-95% pure) purif ied f rom the per i to-  
neal cavity o f  IL -5-transgenic mice (23), since normal  mice 
do not  have appreciable numbers  o f  eosinophils. Cond i -  
t ioned media containing mMCP-5  recombinant protein in- 
duced migrat ion o f  eosinophils in a dose-dependent  man-  
ner  compared to the control  condi t ioned media (Fig. 2 A). 
In three independent  exper iments wi th  different eosinophi l  
and condit ioned media preparations, recombinant mMCP-5  
1942 mMCP-5 in Lung Allergic Inflammation 
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Figure 2. 
Migration (% of Control) 
Chemotactic activity of mMCP-5 on mouse leukocytes m vitro and neutralization of eosmophfl chemotaxas to mMCP-5 by anti-mMCP-5 
antibodies. (A) The indicated mouse leukocyte subtypes were subjected to chemotaxas to different diluuons of the conditioned media contalmng mMCP-5 
(solid diamonds) or of the control mock-conditioned media (empty diamonds). The bars and symbols how the mean and the range for one representative 
experiment out of three (or five for lymphocytes and monocytes). Results are expressed as chemotactic ndex (the ratio between the number of  cells that 
magrated to he sample and the number that migrated to negative control, depicted as bars, axis on left of each plot) and magratlon (the percentage of the 
total number of input cells that migrated to the sample, depicted as lines, axis on the right of each plot). Positive controls (triangles) used for these expen- 
ments were rmEotaxin, rmMIP-lix, and rhlL-8. The migration ofleukocytes to assay media are also included (circle). In chemotaxis assays oflymphocytes 
to undiluted mMCP-5-contaming condmoned media (black bars) or undiluted control conditioned media (white bars), migratory cells were stained with 
anti-B220 or anti-Thy1.2 mAbs, and were analyzed by flow cytometry. (B) Eosinophil rmgration in response to rmMCP-5 is inhibited by specific Abs. 
The same chemotaxis assays described m A for eosinophils were performed. The mMCP-5-contammg or control conditioned media were premcubated 
with or without different concentrations ofpolyclonal antibodies agamst mMCP-5 (see Materials and Methods) or with rabbit Ig fraction as a control for 
15 min at 37°C and, then used for chemotaxis. The chemotaxls of eosmophils to Eotaxin in the presence of the same Abs was used as control for anti- 
MCP-5 Ab specificity. The percentage of  migration observed m the wells containing control supernatant d/or control Ab was subtracted from their 
corresponding experimental points. Data are expressed as the percentage of the posmve control (chemokine alone), which was considered 100%. 
from undiluted conditioned media attracted 10-19% of the 
input eosinophils in transwell chemotaxis assays. In parallel 
assays, only 1.1-2.3% of input eosinophils migrated to the 
control conditioned media (Fig. 2 A). Heparin/cation ex- 
change-purified protein (see Materials and Methods) from 
mMCP-5--containing conditioned media induced the trans- 
migration of ~39% (35-40% migration) of eosinophil in- 
put (Fig. 2 A). 
To evaluate the chemotactic function of mMCP-5 on 
lymphocytes, four independent experiments were per- 
formed and showed that the conditioned media containing 
mMCP-5 induced the migration of lymphocytes from the 
bone marrow (Fig. 2 A) and from the peripheral blood 
1943 Jia et al. 
(PB) (data not shown and Fig. 2 A). We failed to detect re- 
producible chemotaxis of LN- or spleen-derived lympho- 
cytes to mMCP-5 (data not shown) compared to the con- 
trol conditioned media, mMCP-5 attracted a subset (~2%) 
oflymphocytes from both the bone marrow and PB (Fig. 2 
A). In a separate series of experiments, migratory lympho- 
cytes to mMCP-5 were stained with either anti-B220 or 
anti-Thyl mAbs, and the proportion of positive cells for 
each marker was analyzed by flow cytometry. B lympho- 
cytes displayed a stronger esponse to mMCP-5 than T 
lymphocytes, showing a higher chemotactic index (Fig. 2 A). 
Neutrophils and monocytes/macrophages used for in 
vitro chemotaxis assays were isolated from either normal 
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Figure 3. mMCP-5 reduced recruitment ofleukocytes tothe peritoneum. Peritoneal exudate was collected from C57BL/6J mice 2 h after injectmn of 
mMCP-5~containing conditioned media (closed symbols) or control con&tinned media (open symbols). Each dot represents one mdividual mouse analyzed 
(10 mice per group). The bar in each panel represents the mean of the total number of cells of the leukocyte subtype mdicated. For lymphocyte assays, B 
and T cells were also analyzed separately b lmmunophenotypic analysis oflymphocytes recruited to the peritoneum after mMCP-5 mjectlon. 
mouse bone marrow (neutrophils or monocytes) after eryth- 
rocyte lysis and Thyl  + B220 lineage depletion from the 
peritoneal cavities of  IL-5-transgenic mice (monocytes) 
after Gr-1 + Thyl  + B220 hneage depletion, or from the 
peritoneum of mice treated previously with thioglycollate 
(neutrophils or monocytes). Several separate xperiments 
(n = 9) with purified populations or enriched cell prepara- 
tions showed that mMCP-5-containing rather than control 
conditioned media ehcited concentration-dependent chemo- 
taxis of  monocytes isolated from BM (data not shown), 
from the peritoneum of  IL-5-transgenic mice (data not 
shown), or from the peritoneal lavage of  mice treated with 
thioglycollate (Fig. 2 A). mMCP-5 supported the chemo- 
tactic migration exclusively of  microscopically small and 
nongranular monocytes that clustered in a region charac- 
terized by the lowest forward and right angle light scatters 
found among monocytes (defined as Mac1 + Gr-1-;  data 
not shown) when analyzed by flow cytometry. No signifi- 
cant differences were found between mMCP-5-containing 
and control conditioned media in the chemotactic migra- 
tion of  neutrophils isolated either from bone marrow (Fig. 
2 A) or from the peritoneal cavity of  thioglycollate-treated 
mice (not shown). These results were confirmed by the use 
of  mMCP-5 purified by heparin/cation exchange chroma- 
tography in these assays, which showed similar chemotactic 
activity on lymphocytes and monocytes, but not on neu- 
trophils (data not shown). 
To attribute unequivocally all the chemotactic activity 
to eosinophils present in the conditioned media from 
mMCP-5-transfected cells to mMCP-5,  we blocked it in 
vitro with afl]mty-purified polyclonal antibodies raised against 
an mMCP-5 peptide (see Materials and Methods). Anti-  
mMCP-5 antibodies were able to neutralize almost all the 
eosinophil chemotactic activity present in the mMCP-5 
conditioned media, but did not affect the chemotaxis of  
eosinophils to Eotaxin (Fig. 2 B). Similarly, anti-MCP-5 
antibodies were able to neutralize the migration of  lym- 
phocytes and monocytes to mMCP-5 in vitro or in vivo 
(data not shown). 
In Vivo Peritoneal Recruitment of Leukocytes to mMCP-5. 
The injection of  mMCP-5-containing conditioned media 
in mice resulted in a moderate increase in the total number 
of  peritoneal cells that maximized (data not shown) at 2 h 
after mMCP-5 recombinant protein injection (2.3 -+ 0.2 × 
106 cells/mouse) when compared with the number of  cells 
recovered from control mice injected with control condi- 
tioned media (1.7 + 0.1 × 106 cells/mouse) or with PBS 
(1.5 --+ 0.3 X 106 cells/mouse). In these experiments, eosi- 
nophils increased from 0.25 -+ 0.13 X 10 s of  the total cells 
in the peritoneal exudate of  control conditioned media- 
injected mice or PBS-treated littermates to 2.1 + 0.6 X 105 in 
mMCP-5-containing conditioned media-injected mice. 
The injection of  mMCP-5 induced an increase (,'-~l.4- 
fold) in peritoneal lymphocytes that was not observed in 
control conditioned media-injected mice (Fig. 3). mMCP-5 
injection resulted in an increase in peritoneal lymphocyte 
numbers caused by the predominant recruitment of  B220 + 
B lymphocytes (5.7 + 0.4 × 105 cell/mouse in mMCP-  
5-injected mice versus 4.4 + 0.1 x 105 cell/mouse in con- 
trol conditioned media-injected mice or 4.1 -+ 0.2 X 105 
cell/mouse in PBS-treated mice; Fig. 3). The number of  
Thyl.2 + T lymphocytes remained comparable in these 
three different groups of  experimental mice at the same 
time point indicated (5.8 + 2.3 × 104; 4.9 + 1.5 X 104; 
and 5.1 + 1.2 × 104 in mMCP-5- injected mice, control 
conditioned media-injected mice, and PBS-treated mice, 
respectively; Fig. 3). 
No significant increases in the total number of  neutrophils 
or macrophages recovered from the exudates of  mMCP-  
5-injected mice were detected at any time point analyzed 
(Fig. 3 and data not shown). In contrast, there were twice 
as many monocytes 2 h after mMCP-5 injection compared 
1944 mMCP-5 in Lung Allergic Inflammation 
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Figure 4. Expression of mMCP-5 under noninflammatory conditions. 
(A) Northern blot mMCP-5 cDNA with R.NA from different mouse r- 
gans. For confirmation fmMCP-5 expression in some organs, two sepa- 
rately prepared P,.NAs from different mice were included m the Northern 
blot. The size of the hybridizing band is "-'0.5 kb. (B) Immunohtstochem- 
ical analysis of mMCP-5 expression in lymphoid organs. Inguinal LN (I 
and I/) and thyrm (III and IV) from nonimmunized mice were stained 
with anti-mMCP-5 mAbs (// and IV) or with an irrelevant isotype- 
matched negauve control mAb (I andIII). ×400. C, cortex; M, medulla; 
P, paracortex; F, follicle. 
with that recovered from the exudate of mice injected with 
control conditioned media (Fig. 3). 
Pattern of Expression of mMCP-5 under Noninflammatory 
Conditions. Only the LN and thymus expressed consis- 
tently high levels o fmMCP-5  mRNA ('~550 bp; Fig. 4 A). 
mMCP-5  mRNA were also found in heart, skin, lung, and 
spleen by RT-PCR (Fig. 4 A and data not shown), but no 
mMCP-5  mRNA was found constitutively in any other 
tissues of  C57BL/6 mice (Fig. 4 A). 
To determine the distribution of mMCP-5  protein in 
the LN and thymus, immunohistochemical analysis of  sec- 
tions from these organs was performed after staining with 
ant i -mMCP-5 antibodies. In the LN, mMCP-5  staining 
1945 Jia et al. 
was generally localized within stromal-type cells in the 
paracortex and primary follicles (Fig. 4 B, I/). Few, if any, 
lymphocytes or dendritic cells showed immunoreactivity 
(Fig. 4 B and not shown). In the thymus, stromal cells pre- 
dominantly present in the medulla reacted to the mMCP-5  
antibodies (Fig. 4 B, IV). A few cells in the cortex were 
stained, and there seemed to be no immunoreactive thy- 
mocytes present (Fig. 4 B and data not shown). No immu- 
noreactivity to any cell type was recognized in either tissue 
using other irrelevant isotype-matched mAbs ftom the same 
hybridoma fusion (Fig. 4 B, I and III, and data not shown). 
Expression and Function of mMCP-5 in the Lung during Allergic 
Inflammation. Northern analysis showed that mMCP-5  
mR.NA is markedly increased in the lungs of  mice during 
the course of experimental lung eosinophilia (Fig. 5 A), us- 
ing repeated doses of aerosolized OVA for 21 d (10). 
mMCP-5  mRNA expression, which was expressed at very 
low levels in the lung of unmanipulated mice, peaked 3 h 
after OVA challenge on the days analyzed (Fig. 5 A and 
data not shown), thus coinciding with the time point of 
maximal eosinophil accumulation on these days (10). Fur- 
thermore, mMCP-5  protein was localized by immuno-  
staining to alveolar macrophages and to smooth muscle 
cells most strongly (Fig. 5 B). A small number ofleukocytes 
within the large perivascular and peribronchiolar infiltrates 
showed low immunoreactivity (Fig. 5 B and data not 
shown). In areas of leukocyte localization in the lung tissue, 
there was an increase in reactivities of macrophages, 
smooth muscle cells, and other tissue resident cells that cor- 
related with the severity of  the infiltrate (not shown). 
To evaluate the contribution of mMCP-5  to the devel- 
opment of OVA-induced lung eosinophilia, ant i -mMCP-5 
neutralizing Abs were administered 30 min before OVA 
challenge at the time of  maximal eosinophil accumulation 
(days 20 and 21 of  treatment). This antibody preparation 
was shown to block the transmigration of  eosinophils to 
mMCP-5  in vitro (Fig. 2 B). Our results showed that 
blocking o fmMCP-5  in vivo reduced by "-~25% the num- 
ber of  eosinophils that accumulated in the BAL after OVA 
c~rallenge at the same time point indicated (Fig. 5 C). 
Regulation of mMCPo5 Expression In Vivo and In Vitro. 
Based on our previous finding (11) that the presence of  
lymphocytes i absolutely required for eosinophil accumu- 
lation in this model, we studied the regulation of mMCP-5  
mRNA expression in the lungs of  lymphocyte-deficient 
RAG-1 mutant mice (24). Fig. 6 A shows that there was 
strong reduction in the levels of  mMCP-5  mRNA on days 
15 and 18 in OVA-treated RAG-1 mice when compared 
with OVA-treated wild-type controls. It also revealed on 
day 21 a moderate, but notable, reduction in the level of  
expression of  mMCP-5  in the lungs of OVA-treated 
RAG- l -def ic ient  mice (n = 3; Fig. 6 A). In contrast, a 
comparable vel o fmRNA expression ofEotaxin, R.ANTES, 
and MIP-lo~ was found in the lung of  mutant and wild- 
type control mice at each point during the OVA treatment 
(Fig. 6 A). 
To investigate which lymphocyte subtype(s) could be 
involved in the regulation of mMCP-5  expression, North-  
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Figure 5. Expression and fianction 
of mMCP-5 mRNA during OVA- 
induced lung allergic inflammation. 
(A) At the different ime points indi- 
cated atier OVA administration, North- 
em blot analysis was performed to de- 
termine the expression of chemokines 
m the lung. (B) Expression ofmMCP-5 
protein in lungs from OVA-treated 
mice. Immunobastochermcal analysis 
was performed upon lung tissue o- 
lated on day 21 of OVA treatment us- 
ing monoclonal anti-mMCP-5 (see 
Matenals and Methods). Alveolar 
macrophages were prominently stained 
m OVA-treated mice (arrows), and 
smooth muscle cells (arrowheads) of the 
bronchioles were also densely stained 
m treated but not untreated mace. 
(×1,000). (C) Blocking of mMCP-5 
protein with specific neutralizing anta- 
bodies (as used m Fig. 2 B) dunng the 
course of OVA-induced allergic mflam- 
marion (see Materials and Methods). 
Bronchoalveolar lavage was recovered 
from a treated mouse, and eosmophds 
were enumerated. Each dot represents 
a single mouse. 
ern analysis was per formed using RNAs  from the lungs o f  
mice lacking either T and NK cells (CD3~-transgenic 
mice; 14) or CD4 + T cells (CD4-def ic ient  mice; 25) or 
CD8 + T cells (CD8-def ic ient  mice; 26) after OVA treat- 
ment.  We found a comparable level o f  mMCP-5  mRNA 
expression in the lungs o f  these immunodef ic ient  mice 
when compared with that observed in wi ld-type littermates 
during OVA treatment (Fig. 6 A and data not  shown). 
To  address the regulation o f  mMCP-5  expression in dif- 
ferent lung resident cell types present during allergic eosi- 
nophilia, we evaluated the presence o f  mRNA for mMCP-5  
in a panel o f  unstimulated and stimulated cell lines and in 
1946 mMCP-5 in Lung Allergic Inflammation 
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freshly isolated cells of  different lineages by RT-PCR (Fig. 
6/3) or Northern blotting (data not shown). We compared 
this regulation with that of  Eotaxin, whose strong and in- 
ducible mRNA expression was found not to be reduced in 
lymphocyte-deficient mice during OVA treatment (Fig. 6 A). 
No  expression of  mMCP-5  mP, NA was found on 
freshly isolated peritoneal macrophages by lkT-PCI< (Fig. 
6 /3). When macrophages were stimulated in vitro with 
IFN-'y, but not with TNF-o~, however, they expressed 
mMCP-5  mRNA at an easily detectable level (F~g. 6 /3). 
Conversely, the same population of freshly isolated perito- 
neal macrophages stimulated with TNF-oL, but not with 
IFN-y ,  expressed mP,.NA for mEotaxin (Fig. 6/3). Similar 
results were obtained when two macrophage cell lines were 
analyzed (Fig. 6 /3). mMCP-5  mP,.NA expression was 
found in unstimulated or LPS-stimulated P388D1 mac- 
rophages, but not in RAW287 cells (Fig. 6/3). In contrast, 
only RAW287 cells expressed etectable mRNA levels of  
mEotaxin. 
A day 15 day 18 day 21 
mMCP-5 
mEotaxin 
mRANTES 
mMIP-l~t 
~actin 
"0"/+ RMi-lil)J~ +/+ RM,-I ILl)3, +/+ R,M;-I t'l)3t 
[3 , Macrophages ,~/~'¢~' "" 
fre,,hh, isolated cell lines 
- + +  .+ .+ ~ .+ .+  
,,i~tCl-S B [ i  i n  i 1 
inEotaxin / i I l l l l l  i i ~ 
(; - -  m 
Figure 6. Regulat ion of  mMCP-5  nf l~NA expression In VlVO and m 
vitro (A) Expression o fmMCP-5  mRNA in the lungs o f  RAG- l -de f i -  
cmnt n-nce and CD3e-transgenlc  mice dunng lung allergic inf lammation. 
Northern blot analysis was perfomled using total RNAs from lungs 3 h 
after OVA ad~mmstratlon on days 15, 18, and 21 of the treatment Ex- 
presslon of two representanve wild-type mice out of five at each time 
point, two out of five RAG-l-deficient mice on days 15 and 18, and 
three out of five RAG-l-deficient rmce on day 21, as well as one CD3e- 
transgenic mouse on days 15 and 21, and two on day 18 is shown. (B) 
Comparison of the mRNA expression pattern of the mMCP-5 and mEo- 
taxln genes in different cell lines and freshly isolated cells. Total R.NA 
from cells indicated rather without stlmulatmn (-) or after exposure to 
&fferent stimuli (+, see Materials and Methods) wasamplified by RT- 
PCR with in&vldual gene-specific pnmers. Either [3-actln or GAPDH 
was used as the control for these experiments. 
1947 Jla et al. 
mMCP-5  mRNA was also found to be expressed by 
BMCMC and in the mast cell line C1MC/C57.1. In con- 
trast, no mEotaxin mlKNA was found in these two mast 
cell populations, either resting (Fig. 6 B and reference 10) 
or after stimulation with IgE and antigen (data not shown). 
Low but detectable vels of  mMCP-5  mlKNA were ob- 
served in the endothelial cell hne b-End2 with or without 
stimuli (Fig. 6 B), whereas no mMCP-5  mRNA was de- 
tected in nonstimulated or LPS-stimulated N IH3T3 fibro- 
blasts (Fig. 6 B). In contrast, both cell lines express detect- 
able levels of mEotaxin mlKNA. 
Role of mMCP5 in mEotaxin-induced Eosinophil Recruit- 
merit In Viuo and In Vitro. To examine whether the pres- 
ence of  mMCP-5  in the eosmophlhc lung, m which Eo- 
taxin is abundantly expressed, could lead either to a larger 
accumulation of  eosinophils or is a possible mechanism to 
control the inflammatory response, Eotaxin (0.5 bLg/mouse) 
was coinjected in the peritoneum either with 400 lxl/ 
mouse (Fig. 7 A) or 800 Ixl/mouse (data not shown) of  
conditioned media containing mMCP-5 recombinant pro- 
tein or with the same volumes of  the control conditioned 
media. The total number of  peritoneal eosinophils recov- 
ered from mMCP-5- in jected mice or from Eotaxin-injected 
mice 2 h afeer injection was 2.2 + 0.6 X 105 and 1.3 + 0.5 X 
105 cells/mouse, respectively (Fig. 7 A). When both chemo- 
kines were administered simultaneously, the number of  in- 
filtrating eosinophlls was lower (0.8 + 0.3 × 105 cells/ 
mouse, Fig. 7 A) than that found in the peritoneal exudate 
of  m~ce injected with either one alone. In contrast, when 
m/VlCP-5 and mEotaxin were administered simultaneously 
at very low doses (100 and 0.2 Ixg/mouse, respectively), 
the number of  infiltrating eosinophils (0.5 + 0.18 × 10 s 
cells/mouse) was greater than those found when mMCP-5  
or mEotaxin were injected individually at the same doses 
(0.09 --- 0.01 × 105 cells/mouse for mMCP-5  and 0.2 + 
0.03 X 105 cells/mouse for mEotaxin; Fig. 7 A). 
To further define the chemotactic responses of  eosino- 
phils to combinations of  mMCP-5  and mEotaxin, we ex- 
amined them in vitro. The results from two individual ex- 
periments representative of this experimental series (n = 5) 
are shown in Fig. 7 B. mMCP-5  enhanced the migration 
of eosinophils to mEotaxin (from 3 to 10% in the presence 
of &fferent concentration of  mEotaxin). The maximum 
enhancement was reproducibly observed when 10 ng/ml 
of  mEotaxin was combined with undiluted mMCP-5  con- 
ditioned media (Fig. 7 B). As the concentration of  mEot 
was increased from 10 to 250 ng/ml m combination with 
undiluted mMCP-5-conta in ing conditioned media in the 
different experiments, eosmophil migration was enhanced 
to a lesser extent, until no mMCP-5- induced enhance- 
ment of  eosinophil chemotaxis was seen at 250 ng/ml of  
mEotaxin (Fig. 7 /3). Furthermore, mMCP-5  reduced the 
mEotaxin-mduced eosinophil transmigranon in vitro when 
combined with a high concentranon ofmEotaxin (from 50 
to 250 ng/ml, depending on the experiment). This effect 
was not observed when the control conditioned media was 
combined with different concentrations ofmEotaxin in the 
same experiments (Fig. 7 B). We have selected two experi- 
 o
n
 April 16, 2008 
w
w
w
.jem.org
D
ow
nloaded from
 
A , 
~3001 ~ 80 
150-[ 8 [:l • 40" 
o [] • 
1 H 20- 
= 5 • 
v, , ~ , . .~  ~. u , .~,.  ,~ .  
B 
] "~ 
I ~ :~ Exp. 1 "[ TI 
pupematant 1:1 1:1 1:1 1:1 
o ,o oo 
/ 
Figure 7. Effect of mMCP-5 on mEotaxm-lnduced oslnophll migra- 
tion in VlVO and m vitro. (A) Pentoneal eosmophil accumulation i  re- 
sponse to mMCP-5 and mEotaxm comjection. The number of eoslno- 
phlls m the pentoneal exudate of C57BL/6J mice 2 h after Injection with 
mMCP-5 (open circles), mEotaxln (open squares), or both chemokines i- 
multaneously (closed circles) was determined as described in Materials and 
Methods. Values hown in the left panel reflect he number ofeosmophils 
recovered from the peritoneal exudates of mice injected with 400 ~l/mouse 
of mMCP-5-containmg conditioned media and/or 0.5 p~g/mouse of 
mEotaxm m 400 Ixl PBS, whereas values shown in the right panel are 
from mice injected with 100 jxl/mouse of mMCP-5-contalmng condi- 
tioned media and/or 0 2 ~tg/mouse ofmEotaxm  400 pA of PBS. Con- 
trol mice (x) rejected with the same volume of control conditioned media 
and/or 400 Ixl/mouse of PBS (n = 4). Mice injected with Eotaxln (but 
not with MCP-5) were comjected also with the same volume of control 
conditioned media. The bars m each panel represent the mean of the total 
number of eosmophlls recovered from the mice analyzed (each symbol 
represents one individual mouse). (/3) Eoslnophll chemotaxis n response 
to combinations of mMCP-5 and mEotaxm in vitro in the transwell rm- 
gration assay. Two independent expenments out of five are shown. The 
ments to illustrate that we did observe donor - to -donor  
variation in the relative responses to mMCP-5  and mEo-  
taxin, although the pattern discussed above was maintained. 
Discussion 
We have identif ied a novel  mouse CC chemokme that is 
chemotactic for eosinophils, monocytes,  and lymphocytes 
from the lung of  mice during an allergic inf lammatory re- 
sponse characterized by eosinophil ic infiltration. Because o f  
its polyspecificity, its differential gene regulation, and its 
modulatory effect on action o f  Eotaxin, we propose that 
mMCP-5  plays a pivotal role during lung allergic inflam- 
mation. 
mMCP-5  Is a Novel C -C  Chemokine Closely related to Hu- 
man MCP-1.  The amino acid sequence o f  mMCP-5  is 
very similar to that o f  members o f  the human MCP sub- 
branch (27). The first amino acid in the mature protein that 
has been shown to be critical for MCP functions (28) is not 
conserved between mMCP-5  and hMCPs.  Moreover,  com- 
pared to three human MCPs,  mMCP-5  has the longer 
peptide and has an additional cysteine at the COOH termi-  
nus, which might form an additional disulphide bond in 
the protein. It also has a lower  theoretical pI than that o f  
MCPs  (27). mMCP-5  is very similar to hMCP-1  (65%), 
yet is quite different from mMCP-1 / JE  (45%) and from the 
recently described hMCP-4  (,'-~51%; Fig. 1). Three reasons 
lead us to postulate that mMCP-5  is not  the mouse homo-  
logue o fhMCP- l :  (a) the moderate monocyte  chemotactic 
activity o f  low concentrations o f  mMCP-5 ,  and its potent 
activity on eosinophils, which is different f rom the activi- 
ties reported for hMCP-1  (29); (b) the observation that m a 
cross-species Southern blot with hMCP-1  and mMCP-1  
probes, the same band is recognized (Rollins, B., personal 
communicat ion);  and (c) our prel iminary observation that 
under condit ions o f  high stringency, a single band is de- 
tected when an mMCP-5  probe is hybridized to a South-  
ern blot containing human genomic  DNA (experiments 
are underway in our laboratory to clone the ful l- length 
cDNA o f  this putative mMCP-5  homologue  in humans). 
mMCP-5  Is a Chemotactic Factor for Monocytes, Lympho- 
cytes, and Eosinophils In Vitro and In Vivo. In this study, we 
demonstrate that mMCP-5  induces the chemotact ic trans- 
migration o f  monocytes,  lymphocytes, and eosinophils in 
percentage of input cells that rmgrated was measured. Each experimental 
point was tested in duplicate. As a control, the undiluted mock-condi- 
tioned media was mixed with different concentrations of mEotaxm m 
parallel and used m the same assays. The upper panel represents he raw 
data of two representauve expenments out of five that were performed. 
Mlgrauon is expressed as mean values and bars show duplicates. The 
lower panel represents he net difference between the mlgrauon (percent- 
age of input) ofeoslnophds todifferent concentrauons ofmEotaxm in the 
presence or absence of mMCP-5 (as shown m the upper panel). The val- 
ues were calculated by subtracting (individually for each concentration of 
Eotaxan used) the percentage of eosmophil migration induced by mEo- 
taxln in the absence of mMCP-5 (but with the same volume of control 
condmoned media) from the percentage ofeoslnophd migration reduced 
by mEotaxm m the presence ofmMCP-5. 
1948 m/VICP-5 in Lung Allergic Inflammation 
 o
n
 April 16, 2008 
w
w
w
.jem.org
D
ow
nloaded from
 
vitro, but that it has no effect on the chemotaxis of neu- 
trophils (Fig. 2 A). While mMCP-5 induced significant 
chemotaxis of these three leukocyte subsets, eosinophils 
exhibited the greatest response. This response could be 
completely blocked by antibodies against mMCP-5. Al- 
though the migratory response to mMCP-5 in monocyte 
or lymphocyte populations was low (1.5-2%), the chemo- 
tactic index of these cell types was comparable to that found 
in these cell types to other chemoattractants, such as MIP-lot 
or R_ANTES (30). Among lymphocytes, B cells responded 
to mMCP-5 better than T cells did. mMCP-5 is the only 
mouse CC chemokine reported to date that promotes the 
chemotactic migration ofB lymphocytes, although MIP-loL 
has been reported to be chemotactic for human B lympho- 
cytes (31). The differential response of lymphocytes from 
different hemotapoietic organs to mMCP-5 is intriguing, 
and may reflect intrinsic differences in the migratory be- 
havior oflymphocytes from distinct locations. In vivo stud- 
ies showed that mMCP-5 was also effective in recruiting 
leukocytes to the peritoneum after challenge (Fig. 3). 
Stromal Cells in the LN and Thymus Express Constitutively 
mMCP-5. The LN is a highly organized lymphoid tissue 
in which different leukocyte subsets and stromal cells ar- 
range themselves into specialized compartments to which 
particular subsets of lymphocytes migrate in a very specific 
fashion (32, 33). In the thymus, mature and immature thy- 
mocytes interact with stromal cells, and these interactions 
are critical for their maturation. The constitutive mRNA 
expression of mMCP-5 in the LN and thymus (Fig. 4 B), 
together with its chemotactic activity on lymphocytes, 
make it an interesting candidate for participation in this 
process, mMCP-5 does not support T nor B cell prolifera- 
tion in vitro (data not shown). It is notable that we de- 
tected mRNA for mMCP-5 in both skeletal and cardiac 
muscles (Fig. 4 A). We also found expression in heart, 
lung, and skin, but there was great variability between the 
mice that were studied. 
mMCP-5 Is Different from the Other Major CC Chemokines 
in That Its Expression during Allergic Inflammation Is Critically 
Regulated by Lymphocytes. We show here that the expres- 
sion of mMCP-5 mRNA in the lung is maximal 3 h after 
OVA challenge on all days analyzed uring OVA treatment 
(days 15, 18, and 21). However, aclear increase in mMCP-5 
mRNA levels was not seen as treatment progressed. In- 
stead, the levels for mMCP-5 mRNA were almost constant 
3 h after challenge at all time points analyzed (Fig. 5 A), 
contrasting with other CC chemokines in this model (10). 
The pattern of mRNA mMCP-5 expression might reflect: 
(a) its polyspecificity, and thus it is conceivable that this 
chemokine could be involved in the recruitment ofmono- 
cytes (which accumulate in the lung at maximum levels on 
day 15) and of eosinophils and/or lymphocytes (which ac- 
cumulate in the lung at maximum levels on day 21) during 
the allergic process induced by the OVA treatment (10); or 
(b) different activation signals inducing chemokine xpres- 
sion in different cell types, for example, in mast cells, 
mMCP-5 is readily expressed, whereas Eotaxin is not. 
Blocking the mMCP-5 protein with specific antibodies in 
1949 Jia et al. 
vivo during the induction of lung eosinophilia resulted in a 
significant decrease (N25%, P <0.05) in the number of 
eosinophils that accumulated in the lung. These resnlts in- 
dicate that mMCP-5 contributes either directly or indi- 
rectly to the development of lung eosinophilia in this 
model. Although other eosinophilic hemokines are ex- 
pressed uring the course of the OVA treatment (Fig. 6 A), 
m_MCP-5 and RANTES are the predominant ones at ear- 
lier points of this particular inflammatory esponse (day 15). 
Accordingly, on day 15 of the OVA treatment, he block- 
age of mMCP-5 with Ab revealed that at this time point, 
thzs chemokine is responsible for 80% of the accumulation 
of eosinophils in the lung (Gonzalo, J.A., and J.C. Gutier- 
rez-Ramos, unpubhshed data). 
Analysis of lung tissue from mice that were exposed to 
OVA (day 21, 3 h after challenge) revealed intense staining 
of alveolar macrophages and smooth muscle cells (Fig. 5 B) 
and much less intense staining of epithelial and possibly en- 
dothelial cells and fibroblasts (Fig. 5 B), which are well 
characterized for their ability to produce other chemokines, 
such as MCP-1 and MIP-1 (34). It is notable, however, 
that the cell type primarily responsible for Eotaxin produc- 
tion is the alveolar epithelium (10, 11). We failed to deter- 
mine by immunostaining if mast cells have MCP-5 immu- 
noreactivity in vivo. 
A hallmark of mMCP-5, which distinguishes it from the 
other CC chemokines present in the eosinophilic lung, is its 
differential mRNA regulation during lung allergic inflam- 
mation. Only mMCP-5 mRNA expression was signifi- 
cantly reduced in the lung of OVA-treated, RAG-1 mu- 
tant mice (Fig. 6 A). This suggests that lymphocytes play an 
important role in the expression of mMCP-5 during aller- 
gic inflammation. Furthermore, similar levels of expression 
of mMCP-5 mRNA in the lungs of mutant mice lacking 
T cells (CD3e-transgenlc mice, CD4-deficient mice, and 
CD8-deficient mice) and wild-type littermates during OVA 
treatment demonstrate that B lymphocytes (P,.AG-l~teficient 
mice) but not T lymphocytes are essential for mMCP-5 
expression (Fig. 6 A and data not shown). 
It should be emphasized that no mMCP-5 immunoreac- 
tivity was found in infiltrating leukocytes in lung sections 
of OVA-treated mice (Fig. 5 B), and therefore it is unlikely 
that the strong reduction in mMCP-5 mRNA levels in the 
lung of OVA-treated, RAG-l-deficient mice could be at- 
tributed directly to the absence of few, if any, mMCP- 
5-expressing lymphocytes. Rather, we favor the hypothesis 
that B lymphocytes deliver key signals to induce mMCP5 
expression by macrophages, mooth muscle cells, and/or 
other tissue resident cell types. This allows the hypothesis 
that regulation of the expression of mMCP-5 and of, for 
example, Eotaxin might be governed by different signals. 
Correspondingly, we found almost opposite patterns of ex- 
pression for Eotaxin and mMCP5 mRNAs after activation 
of primary cultures ofmacrophages or mast cells (mMCP-5 
mRNA can be produced by the mast cells studied here, but 
not Eotaxin mRNA [Fig. 6 B and reference 10]). More- 
over, different mMCP-5 and mEotaxin mlLNA expression 
was found in various cell lines representing some of the cell 
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lineages that may produce mMCP5 in the inflamed lung 
(Fig. 6/3). 
The Migration of Eosinophils to Eotaxin Is Modulated by 
mMCP-5 In Vivo and h~ Vitro. Our results demonstrate that 
doses of  either mMCP-5  or mEotaxin, which by them- 
selves are each able to induce a significant increase m the 
number of infiltrating eosinophils, fail to exert the same ef- 
fect when coinjected (Fig. 7 A). In contrast, doses of both 
chemokines that separately elicit a small but significant 
peritoneal recruitment of  eosinophils howed a cooperative 
effect in the recrultment of eosinophils when simultaneously 
injected (Fig. 7 A). Mso in vitro, our results showed that a 
constant amount of  mMCP-5  can either enhance or re- 
duce the chemotaxis of eosinophils to Eotaxin. Therefore, 
mMCP-5  modified the bell-shape curve of the response to 
Eotaxin (Fig. 7 /3). These results suggest that mMCP-5  
would cooperate with low amounts of Eotaxin in augmenting 
the directed movement  of  eosinophils in the chemotaxis as- 
say. When a certain concentration of Eotaxin is reached in 
the assay, however, the presence of mMCP-5  reduces the 
response to Eotaxin. Experiments are underway to determine 
if MCP-5  and Eotaxin share a receptor on eosinophils. 
Our  initial work on the novel chemokine mMCP-5  has 
focused on the characterization of  its possible function in 
allergic inflammatory reaction situations. The expression 
and function of mMCP-5  have unique characteristics dur- 
ing lung allergic inflammation that distinguish it from other 
CC chemokines tudied. 
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